The company will prioritise investment for in-house innovation over large M&A deals, bucking the trend across pharma.

Bank of America Global Research upped its rating on Regeneron Pharmaceuticals and its price target to $860 because it has a ...

Celltrion negotiates patent deal after German court halts Eydenzelt sales Celltrion says talks under way to settle patents ...

Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...

The firm now models $4.35 billion in U.S. Eylea franchise revenues for 2026, well above the $3.86 billion consensus. BofA also highlighted upside from Dupixent, noting it “continues to deliver growth” ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Eylea HD improved vision with extended dosing intervals ...

Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA ® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...

Regeneron Pharmaceuticals REGN announced that it has met the primary endpoint in a late-stage study evaluating Eylea HD (aflibercept) Injection 8 mg to treat patients with macular edema following ...

The U.S. Food and Drug Administration has accepted for Priority Review Regeneron Pharmaceuticals, Inc.’s (NASDAQ:REGN) supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) ...